Champions Oncology, Inc.

NASDAQ:CSBR

Biotechnology

Healthcare
$4.44 -1.17%

-$0.08 today

Market cap
$61.80M
Beta
0.40
P/E (TTM)
-41.0
EPS (TTM)
-$0.16
52W Low $5.50High $9.63

Volume 0.01M

Average 0.01M

CSBR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Champions Oncology, Inc.NASDAQ: CSBR

Research & Development · Q3 FY2026 · quarter ended Jan 2026

Research & development growth accelerates

Q3 FY2026 research & development of $2.27M rose 32.1% year over year, ahead of the +29.2% change in trailing-twelve-month research & development. Sequentially, it fell 13.2% from the prior quarter. Over 3 fiscal years it compounded at -10.0% a year.

Context

  • Research & development amounted to 12.0% of revenue in FY2025, down 7.0 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +32.1% holds above the trailing-twelve-month pace of +29.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJan 2026
$2.27M-13.2% QoQ
Last fiscal yearApr 2025
$6.83M-28.5% YoY
LTMJan 2026
$8.93M+29.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.1%——
1 year-28.5%——
3-year CAGR-10.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
6.83M USD
Year-over-year change
-28.5%
4-year CAGR
-1.3%

Research & Development vs competitors

How CSBR compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +29.2% is the highest of 10, against a peer median of -29.1%.
  • Research & development amounts to 15.4% of revenue for CSBR, versus a peer median of 3629.9%.
CSBR Competitors
Research & Development for CSBR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$151.37M USD-38.7%+6.7%152.0%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$71.8M USD+27.7%+16.5%—
CNTBConnect Biopharma Holdings LimitedFY2025$37.8M USD+29.2%-26.9%59059.4%
STTKShattuck Labs, Inc.LTM Mar 2026$36.3M USD-40.4%-24.8%3629.9%
KLRSKalaris Therapeutics IncLTM Mar 2026$32.3M USD-29.1%+37.8%—
IMAImageneBio IncLTM Mar 2026$30.77M USD+23.4%-23.7%—
IFRXInflaRx N.V.LTM Mar 2026€22.87M EUR-34.8%-11.8%77989.1%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$10.18M USD-92.4%-48.4%44.0%
CSBRChampions Oncology, Inc.LTM Jan 2026$8.93M USD+29.2%-10.0%15.4%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$5.77M USD-21.5%-38.7%—
Peer median (excluding CSBR) —-29.1%-23.7%3629.9%

Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue41.04M49.11M53.87M50.16M56.94M
Cost of Revenue21.45M23.63M29.53M29.4M28.39M
Gross Profit19.59M25.48M24.34M20.75M28.56M
Gross Margin47.7%51.9%45.2%41.4%50.1%
Research & Development7.2M9.37M11.55M9.54M6.83M
Selling, General & Admin12.03M15.5M17.24M18.13M16.88M
Operating Expenses19.23M24.87M28.79M27.68M23.71M
Depreciation & Amortization1.18M1.63M2.25M1.87M1.64M
EBITDA1.55M2.21M(3.02M)(5.44M)6.27M
EBITDA Margin3.8%4.5%-5.6%-10.8%11.0%
Operating Income366K607K(4.45M)(6.92M)4.85M
Operating Margin0.9%1.2%-8.3%-13.8%8.5%
Interest Income00000
Interest Expense00000
Other Income / Expenses71K(24K)(818K)(387K)(220K)
Income Before Tax437K583K(5.27M)(7.31M)4.63M
Pre-Tax Margin1.1%1.2%-9.8%-14.6%8.1%
Income Tax Expense75K35K68K(32K)(75K)
Net Income362K548K(5.34M)(7.28M)4.7M
Net Margin0.9%1.1%-9.9%-14.5%8.3%
EPS (Basic)0.030.04(0.39)(0.54)0.34
EPS (Diluted)0.020.04(0.39)(0.54)0.33
Weighted Avg Shares13.14M13.2M13.54M13.55M13.66M
Weighted Avg Shares (Diluted)14.57M14.16M13.54M13.55M14.27M

Champions Oncology, Inc.

NASDAQ:CSBR

Intrinsic Alpha fair value

Locked

Current Price

$4.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.